Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot |
| Sample | Human GBM cell lines(U87, U251), malignant glioma tissues |
| Expression Pattern | down-regulated |
| Function Description | Collectively, our findings revealed that downregulated lncRNA MEG3 could promote glioma cell proliferation through targeting Wnt/B-catenin signaling, which mainly influenced cell cycle.Despite multiple efforts that have been made in the recent years, the prognosis of patients diagnosed with gilomas still remains unsatisfied, with a median survival of only 15 months.1 |
| Pubmed ID | 29027534 |
| Year | 2017 |
| Title | Long non-coding RNA MEG3 promotes the proliferation of glioma cells through targeting Wnt/B-catenin signal pathway. |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |